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Abstract
Introduction Blood-based sample collection is a challenge, and dried blood spots (DBS) represent an attractive alternative. 
However, for DBSs to be an alternative to venous blood it is important that these samples are able to deliver comparable 
associations with clinical outcomes. To explore this we looked to see if lipid profile data could be used to predict the con-
centration of triglyceride, HDL, LDL and total cholesterol in DBSs using markers identified in plasma.
Objectives To determine if DBSs can be used as an alternative to venous blood in both research and clinical settings, and 
to determine if machine learning could predict ‘clinical lipid’ concentration from lipid profile data.
Methods Lipid profiles were generated from plasma (n = 777) and DBS (n = 835) samples. Random forest was applied to 
identify and validate panels of lipid markers in plasma, which were translated into the DBS cohort to provide robust measures 
of the four ‘clinical lipids’.
Results In plasma samples panels of lipid markers were identified that could predict the concentration of the ‘clinical lipids’ 
with correlations between estimated and measured triglyceride, HDL, LDL and total cholesterol of 0.920, 0.743, 0.580 and 
0.424 respectively. When translated into DBS samples, correlations of 0.836, 0.591, 0.561 and 0.569 were achieved for 
triglyceride, HDL, LDL and total cholesterol.
Conclusion DBSs represent an alternative to venous blood, however further work is required to improve the combined lipi-
domics and machine learning approach to develop it for use in health monitoring.
Keywords Lipidomics · Total cholesterol · Triglyceride · HDL · LDL
1 Introduction
Traditionally, in high-income countries there is significant 
infrastructure to facilitate preclinical population health 
monitoring and research that is not present in low income 
countries leaving a significant unmet need for research and 
health monitoring (Kreuter et al. 2016; Johannessen 2010). 
Collecting samples in a hospital setting is still relatively 
straight forward, however owing to the difficulty, expense 
(relative to income) and risk of infection only individuals 
with serious or life-threatening symptoms are usually taken 
to hospital meaning that a sample cohort collected in a hos-
pital alone would be biased.
In low income settings sending teams into the commu-
nity to collect samples is one part of the solution to this. 
However, venous blood samples will need to be processed 
and frozen within a few hours of sample collection (Yin 
et al. 2015) and in rural areas of an LIC access to labora-
tory facilities to do this is unlikely to be available. It is with 
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these limitations in mind that dried blood spots represent an 
attractive alternative to venous blood collection as it ena-
bles samples to be collected in remote geographic locations 
because processing the sample for storage does not require 
laboratory facilities (Spooner et al. 2019; Li and Tse 2010). 
The ability to collect smaller blood volumes is also attractive 
for working with fragile patient populations in LIC settings 
e.g. malnourished infants (Spooner et al. 2019; Lakshmy 
et al. 2014; Komada et al. 2015). In addition to this Prentice 
et al. (Prentice et al. 2013) showed that whilst room tem-
perature storage of DBS samples for two years does lead 
to significant differences in metabolite composition, room 
temperature storage for just a week has very little effect, 
meaning that there can be a short delay between sample col-
lection and storage at either − 20 °C or − 80 °C. These find-
ings are consistent with other studies that have shown that a 
range of analytes including lipids, HIV antibodies and drugs 
including ceftriaxone and cocaine are stable on DBS cards 
stored at room temperature for short periods (Kyle et al. 
2017; Page-Sharp et al. 2016; Yassin et al. 2013; Alfazil 
and Anderson 2008). In the context of research, where large 
sample cohorts can take several years to collect and espe-
cially when repeat sampling is involved, the effect of long 
term storage at − 80 °C is also an important experimental 
factor to consider. Prentice et al. also looked at the stability 
of lipid analytes in DBS stored at both − 20 °C and − 80 °C 
and demonstrate that storage at − 80 °C for 2 years had a 
minimal effect on the lipid composition of the DBS samples 
(Prentice et al. 2013).
For both research and health care monitoring it is impor-
tant to determine if there is good concordance in the con-
centrations measured in both DBS and plasma samples. 
There is a significant body of literature looking at how to 
analyse a wide range of drug analytes in these samples (Wil-
helm et al. 2014; Elst et al. 2013; Manicke et al. 2011), with 
DBS samples being standardly used pharmokinetic studies 
in neonates and young children (Abu-Rabie and Spooner 
2009). An array of endogenous compounds have also been 
measured from dried blood spots including HbA1c (Crim-
mins et al. 2014; Lacher et al. 2013), total cholesterol (Abhi-
jit et al. 2016; Miller et al. 2015; Corso et al. 2016), HDL 
(Lacher et al. 2013; Miller et al. 2015; Samuelsson et al. 
2015), triglyceride (Lakshmy et al. 2012,2010; Quraishi 
et al. 2006) and CRP (Elst et al. 2013) among others. A 
detailed discussion of this literature is beyond the scope of 
this manuscript and there are several excellent reviews on 
this subject (Spooner et al. 2019; Zakaria et al. 2016; Chance 
et al. 2014).
Many of these studies have been successful and achieved 
good concordance between the concentration of a given 
analyte when measured in both DBS and plasma samples 
making them useful tools in research and healthcare mon-
itoring. For example Lakshmy et al. was able to achieve 
a correlation of r = 0.797 between concentrations of total 
cholesterol measured in DBS and serum samples (Lakshmy 
et al. 2012). This is broadly in keeping with the other results 
reported in the literature with Samuelsson et al. reporting 
r = 0.480 (Samuelsson et al. 2015), Corso et al. achieving 
r = 0.611 (Corso et al. 2016) and Lacher et al. an  R2 of 0.340 
(Lacher et al. 2013) between concentrations of total choles-
terol measured in DBS and serum samples. This concord-
ance between studies is not just seen for total cholesterol 
with Quraishi et al. obtaining a correlation of r = 0.970 
between triglyceride concentration measured in DBS and 
plasma samples (Quraishi et al. 2006) with subsequent stud-
ies achieving correlations of r = 0.838 and r = 944 (Lakshmy 
et al. 2012,2010). The ability to obtain a good measure of a 
given analyte with a strong correlation between plasma and 
DBS concentrations is not the only factor in ensuring that 
the two sample types are comparable; it is also important 
to ensure that the relationship between a given analyte and 
a clinical outcome measure present in the original blood 
sample are maintained in the DBS sample. For example if 
we consider measurement of activity of steraoyl-CoA desat-
urase using the ratio of PC(32:1) to PC(32:0), and either 
of PC(32:1) or PC(32:0) are diffuse differently across the 
sorbent or have differing extraction recoveries then this ratio 
will be changed giving false reading for the activity of this 
enzyme.
With this in mind the aims of this study were twofold. 
Firstly, we aimed to determine the comparability of results 
obtained from interrogating complex lipidomics data gen-
erated from DBS and plasma samples. We will do this by 
using random forest machine learning, which will be applied 
to lipid profile data generated from human plasma samples 
to predict the circulating concentration of four clinically 
important lipoproteins, triglyceride, HDL, LDL and total 
cholesterol. Subsequently we will measure these biomarkers 
in DBS samples and determine if these biomarkers can pre-
dict the concentration of these lipoproteins. We have chosen 
to use samples from the Dutch famine birth cohort and the 
Amsterdam Born Children and their Development cohorts 
rather than freshly collected samples as this better reflects 
the research cohorts that these developed approaches will 
be applied to. We have chosen to work with dried blood 
spot samples where the concentration of these lipoproteins 
was measured in a paired capillary blood sample rather than 
measured directly from the DBS. We have made this deci-
sion as we specifically want to DBS lipid profile data to 
predict the concentrations of these lipoproteins in blood and 
whilst measuring them in the DBS sample would provide an 
accurate surrogate of the blood concentration measuring it 
directly from the blood is preferable. Our second aim was 
to see if the estimated concentrations that we obtained from 
the DBS samples were accurate enough to be used in clinical 
practice and thus the bias of health care monitoring.
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2  Materials and methods
2.1  Sample description
2.1.1  Dutch Famine Birth Cohort (DFBC)
The Dutch Famine Birth Cohort is a historical cohort of 
2,414 men and women born in the Wilhemina Gasthuis 
hospital in Amsterdam between the 1st of November 1943 
and 28th of February 1947. The selection procedures of 
this cohort have been described in detail previously (Lumey 
et al. 1993). In the present study, we analysed 777 plasma 
samples collected between 2002 and 2004 from individuals 
aged 55.7 to 60.8 years old, with all samples stored at -80 °C 
prior to analysis. The study was approved by the local Medi-
cal Ethics committee and conducted in accordance with the 
Helsinki declaration. All participants gave written informed 
consent.
2.1.2  Amsterdam Born Children and their Development 
(ABCD) cohort
The Amsterdam Born Children and their Development 
cohort is a large prospective birth cohort established in 
2003–2004 in which mothers, fathers and their children are 
followed from pregnancy to adulthood, examining parental 
factors and their influence on the child’s health and devel-
opment (Eijsden et al. 2011). Dried blood spots were col-
lected in 2015–2016 when the children were between 11 
and 13 years old with samples collected by numbing the 
participants finger before pricking it and dropping blood 
onto Whatman 903 cards filled with a solution of 5 mg but-
ylated hydroxytoluene (BHT) per 10 ml ehthanol. Samples 
were subsequently dried at room temperature, catalogued 
and stored at − 80 °C prior to analysis. Lipid profiles were 
generated from 835 dried blood spot samples collected from 
children aged between 11.1 and 13.0 years (Eijsden et al. 
2011). The study was approved by the local Medical Ethics 
committee and conducted in accordance with the Helsinki 
declaration. All participants and their parents gave written 
informed consent.
2.2  Measurement of ‘clinical lipids’
In the Dutch Famine Birth Cohort, fasting blood was drawn 
for analysis of Low Density Lipoprotein (LDL)-cholesterol, 
High Density Lipoprotein (HDL)-cholesterol and triglycer-
ide. HDL-cholesterol and triglyceride were measured using 
an enzymatic colorimetric reagent test using a P-800 Modu-
lar (Roche/Hitachi), with LDL-cholesterol calculated using 
the Friedewald formula and total cholesterol determined by 
combining the concentration of HDL and LDL cholesterol 
(Lumey et al. 1993). In the ABCD cohort samples were col-
lected after a 3 h fasting period with capillary blood from 
a finger prick was collected within a capillary tube within 
10 s with the sample subsequently transferred to the test cas-
sette with TG, TC, HDL, and LDL concentration determined 
using the Cholestec LDX Analyzer (Eijsden et al. 2011).
2.3  Preparation of plasma samples
Samples were extracted from plasma (which was stored 
at − 80 °C until assay) as described previously (Harshfield 
et al. 2019). In short: 100 µl of LC–MS grade water and 
150 µl of internal standard mix (Table S1) were added to 
15 µl of plasma in a 96 well glass coated plate prior to mix-
ing for 10 s. Subsequently, 750 µl of LC–MS grade methyl-
tertiary butyl ether (MTBE) and a further 200 µl of LC–MS 
grade water were added to each well before shaking for 10 s. 
Once mixed, plates were spun at 845×g for 2 min to achieve 
phase separation with 25 µl of the upper organic phase trans-
ferred to a new glass coated plate with 90 µl of MS-mix 
(7.5 mM ammonium acetate in IPA:CH3OH 2:1), which was 
subsequently added to each well.
2.4  Preparation of dried blood spot samples
Dried blood spot samples were prepared as described pre-
viously (Koulman et al. 2014). In short: 100 µl of LC–MS 
grade water and 150 µl of internal standard mix (Table S1) 
were added to a 3.2 mm diameter dried blood spot in a 96 
well glass coated plate prior to mixing for 10 s. Subse-
quently, 750 µl of LC–MS grade methyl-tertiary butyl ether 
(MTBE) and a further 200 µl of LC–MS grade water were 
added to each well before shaking for 10 s. Once mixed, 
plates were spun at 845 × g for 2 min to achieve phase sepa-
ration with 150 µl of the upper organic phase transferred 
to a new glass coated plate and was dried down under a 
continuous stream of nitrogen. The dried samples were then 
reconstituted in 25 µl of MTBE to which 90 µl of MS-mix 
(7.5 mM ammonium acetate in IPA:CH3OH 2:1) was sub-
sequently added to each well.
2.5  Preparation of quality control samples
Three levels of quality controls samples 100% serum, 50:50 
(v:v) serum:water and 25:75 (v:v) serum:water were pre-
pared from a pooled serum sample with 15 µl extracted 
following the same procedure applied to DBS and plasma 
samples. In addition to being used to assess and correct 
plate to plate variance the quality control levels are also 
used to aid signal identification with real signals showing 
a linear increase in abundance with an increase in serum 
concentration.
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2.6  DIMS lipidomic profiling
Samples were infused into an Exactive Orbitrap (Thermo, 
Hemel Hempstead, UK) using a Triversa Nanomate (Advion, 
Ithaca, USA). Data collection began 20 s after the infusion 
began, initially analysing samples in the positive ionisation 
mode with an ionisation voltage of 1.2 kV applied. Data 
was acquired between 150 and 2000 m/z with a scan rate 
of 1 Hz giving a mass resolution of 65,000 at 400 m/z. A 
more detailed description of the instrument parameters can 
be found in Harshfield et al. (2019).
2.7  Processing of lipidomic data
Raw data files were converted to.mzXML files using msCon-
vert (ProteoWizard) (Chambers et al. 2012), and were sub-
sequently processed in R (version 3.2.2) using an in house 
script to compare spectra against a list of 1649 lipid species, 
with a relative intensity and mass deviation value recorded 
for each lipid in every sample. We applied 4 filtering steps 
for quality control of the data and focus subsequent analysis 
on analytically robust signals. The first step was to remove 
lipids with a mean mass deviation between expected and 
recorded mass of greater than 5 ppm, the second step was 
to remove signals with an average intensity in the samples 
less than 5 times greater than in the blanks. The third step 
was to remove signals with 0 values in greater than 10% of 
samples. The final step was to remove lipids with an r < 0.9 
in our QC dilution series.
In this study, the ‘discovery’ and ‘validation’ cohort were 
processed in parallel to ensure that datasets contained the 
same lipid variables. To control for potential differences in 
the volume of blood sampled from each blood spot all data 
was normalised to total signal intensity, this was done by 
calculating the total abundance of all of the lipid signals 
within a given sample then dividing the abundance of each 
of these signals by the total. After normalisation data was 
subsequently mean centred to allow for a direct comparison 
between the two cohorts. The data in the DBS cohort was 
filtered using the same steps as the plasma samples but was 
processed independently of the plasma samples as the com-
position of DBS samples will be different to that of plasma 
samples (Table 1).
2.8  Statistical analysis
Data analysis was performed for each of the four ‘clinical 
lipid’ markers (triglyceride, LDL, HDL and total cholesterol) 
independently. The analysis was performed in two stages, in 
the first stage of the analysis, we applied a random forest 
model to all of the data in the ‘discovery’ cohort (the DFBC) 
to identify a panel of lipid biomarkers capable of robustly 
predicting the concentration of the clinical biomarker. This 
was done by splitting the samples into training and test sets 
(samples split 70:30 respectively) and calculating a random 
forest model in the training set and assessing its performance 
in the test set. To determine the number of lipids to include 
in the predictive panel, iterative random forest models were 
calculated using the highest ranked variable from the ‘all 
data’ model first and then adding additional variables to 
each model (one at the time) until we achieved a model that 
performed as well as the model calculated using all lipids.
In the second stage, we determined if the panel of lipid 
biomarkers identified in the plasma samples from the DFBC 
could be used to predict the concentration of the clinical 
markers in the ‘validation’ cohort. This was done by dividing 
the DBS cohort (ABCD cohort) into a training and test set 
(70:30) and calculating a random forest model in the training 
set and assessing its predictive performance in the testing set 
based on the correlation between the measured and predicted 
concentration of the clinical biomarker.
The relationships between individual lipid species and 
given clinical biomarker concentrations were determined 
using generalised linear models (GLM) applied to the whole 
of the dataset. All models were calculated in ‘R’ (version 
3.4.2). Controlling for type 1 errors was performed by deter-
mining if p-values passed a Bonferroni adjusted significance 
threshold of p = 0.0004 calculated based on all 125 lipids 
measured in this study.
3  Results
In plasma samples 163 lipids from 11 classes passed quality 
control procedures, whilst 118 lipids from 11 classes were 
identified in the dried blood spot samples with 71% of the 
lipids measured in DBS also measured in plasma.
Table 1  Clinical characteristics of the sample cohorts used in this 
study
BMI body mass index, HDL high density lipoprotein, LDL low den-
sity lipoprotein, TriG triglyceride
*** < 0.0001
Dutch famine 
birth cohort
Amsterdam born children 
and their development 
cohort
Sample  No 777 835
Gender (% female) 54.2% 50.6%
Age (years) 58.3 ± 1.0 11.8 ± 0.4***
BMI 28.6 ± 4.9 17.6 ± 2.5***
TriG (mmol/L) 1.53 ± 1.00 0.97 ± 0.54***
HDL (mmol/L) 1.51 ± 0.42 1.48 ± 0.32***
LDL (mmol/L) 3.63 ± 1.00 2.17 ± 0.55***
Total Cholesterol 
(mmol/L)
5.83 ± 1.08 4.09 ± 0.65***
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3.1  Estimation of triglycerides concentration
A panel of 12 lipids (Table S2) produced a model with a 
mean square of residual (MSR) of 0.199 in the training set 
(Table S2) and a correlation of r = 0.914 and p = 7.0 × 10–92 
between estimated and measured triglyceride in the test set 
(Fig. 1a). With the exception of DG(34:2) and DG(36:2), 
which were not detected in lipid profiles generated from 
DBS samples the remaining 10 lipids were used to generate 
a random forest model with an MSR of 0.111 in the training 
set (Table S2), with estimated and measured triglyceride 
correlating with r = 0.836 and p = 1.9 × 10–63 in the test set 
(Fig. 1b). The samples in the test set of the DBS cohort were 
divided into quartiles based on their measured and their pre-
dicted TriG independently with the number of samples that 
were in the same quartile for both measured and predicted 
TriG concentration being recorded. The percentage overlap 
was higher in all quartiles than the 25% that we would expect 
to see by chance. It is also interesting to note that there was 
a higher percentage overlap in the 1st and 4th quartiles com-
pared to the overlap in the 2nd and 3rd quartiles (Table 2).
3.2  Estimation of HDL concentration
In the discovery cohort a panel of 11 lipids (Table S3) was 
identified that generated a random forest model with an 
MSR of 0.082 in the training set (Table S2), with a correla-
tion of r = 0.748 and p = 4.5 × 10–42 between estimated and 
measure HDL in the test set (Fig. 2a). All 11 of the lipids of 
panel identified in the discovery cohort of plasma samples 
were measured in the DBS samples with these lipid used to 
generate a random forest model with an MSR of 0.068 in the 
training set (Table S2), with a correlation of r = 0.591 and 
p = 9.4 × 10–21 between estimated and measure HDL concen-
tration in the test set (Fig. 2b).
3.3  Estimation of LDL concentration
In plasma samples random forest identified a 10 lipid panel 
of markers (Table S4) with an MSR of 0.811 in the train-
ing set (Table S2), with an estimated and measured LDL 
concentration correlating with r = 0.556 and p = 5.1 × 10–21 
in the test set (Fig. 3a). In the DBS samples from the ABCD 
cohort CE(14:0) and TG(47:4) were not detected in the 
lipid profiles generated from DBS samples.A random for-
est model generated using the 8 remaining lipids from the 
predictive panel with an MSR of 0.231 in the training set 
(Table S2), and a correlation of r = 0.561 and p = 4.6 × 10–21 
between estimated and measured LDL concentration in the 
test set (Fig. 3b).
The quartile distribution of LDL showed that the percent-
age overlap was higher in all quartiles than the 25% that we 
would expect to see by chance (Table 2).
3.4  Estimation of total cholesterol concentration
A panel of 11 lipids (Table S5) were used to generate a ran-
dom forest model with an MSR of 1.05 in the training set 
(Table S2), and a correlation of r = 0.424 and p = 1.8 × 10–11 
between estimated and measured total cholesterol in the test 
set (Fig. 4a). In the ABCD cohort, LPC(20:4), CE(14:0), 
CE(16:1) and PC-O(40:5) which form part of the predic-
tive panel identified in plasma samples were not detected in 
the lipid profiles generated from DBS samples. A random 
forest model generated using the remaining 7 lipids with an 
MSR of 0.288 in the training set (Table S2), with estimated 
and measured total cholesterol concentration correlating 
with r = 0.569 and p = 9.3 × 10–22 (Fig. 4b). Again, as with 
the quartile distribution of the other lipids, the percentage 
overlap for total cholesterol was higher in all quartiles than 
the 25% that we would expect to see by chance (Table 2).
Fig. 1  Scatter plots showing predicted vs. measured Triglyceride concentration in discovery and validation analysis. a Results of model trained 
and tested in ‘discovery’ cohort. b Results of models trained and tested in DBS ‘validation’ cohort using lipid markers identified in plasma
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3.5  Univariate analysis of lipid associations 
with lipoprotein concentration
Of the 44 lipid associations from the 4 predictive panels 
8 (18%) were not measured in the DBS samples whilst 36 
(82%) were successfully validated with a strong correlation 
(r = 0.917) observed between the correlation coefficients 
measured calculated between the individual lipid abundance 
and lipoprotein concentration in both plasma and DBS 
samples.
Of the 12 lipids used to predict triglyceride concen-
tration all significantly associated with TriG concentra-
tion passing bonferroni correction at (p < 0.0004) in 
both DFBC and ABCD cohorts, except for DG(34:2) 
and DG(36:2) which were not measured in DBS samples 
(Table S2).
Table 2  Comparison of relative distribution based on quartiles of measured clinical lipid concentration and the concentration predicted from 
dried blood spot samples
Overlap* the number of samples with the measured and predicted lipid concentrations falling in the same quartile. Triglyceride ‘Desir-
able’ < 1.7  mmol/l, ‘Borderline’ 1.7–2.2  mmol/l, ‘Poor’ > 2.2  mmol/l, HDL ‘Desirable’ > 1.5  mmol/l, ‘Borderline’ 1.5–1.1  mmol/l, 
‘Poor’ < 1.2.2  mmol/l, LDL ‘Desirable’ < 2.6  mmol/l, ‘Borderline’ 2.6–5.0  mmol/l, ‘Poor’ > 5.0  mmol/l, Total cholesterol ‘Desira-
ble’ < 5.2 mmol/l, ‘Borderline’ 5.2–6.2 mmol/l, ‘Poor’ > 6.2 mmol/l
Dutch Famine Birth Cohort (plasma)
‘Desirable’ ‘Borderline’ ‘Poor’
Triglyceride Overlap* 144 16 34
% Overlap 90.5 64.0 72.3
HDL Overlap* 82 23 45
% Overlap 73.2 56.1 57.7
LDL Overlap* 30 147 13
% Overlap 85.7 89.1 41.9
Total Cholesterol Overlap* 3 135 12
% Overlap 100.0 64.6 63.1
Amsterdam Born Children and their Development Cohort (dried blood spots)
1st Quartile 2nd Quartile 3rd Quartile 4th Quartile
Triglyceride Overlap* 36 32 32 44
% Overlap 60.0 53.3 53.3 73.3
HDL Overlap* 37 24 21 35
% Overlap 61.7 40.0 35.0 58.3
LDL Overlap* 34 20 22 36
% Overlap 56.7 33.3 36.7 60.0
Total Cholesterol Overlap* 35 21 20 34
% Overlap 58.3 35.0 33.3 56.7
Fig. 2  Scatter plots showing predicted vs. measured HDL concentration in discovery and validation analysis. a Results of model trained and 
tested in ‘discovery’ cohort. b Results of models trained and tested in DBS ‘validation’ cohort using lipid markers identified in plasma
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With the exception of PC(38:5) all significantly asso-
ciated with HDL concentration passing bonferroni cor-
rection at (p < 0.0004) in both DFBC and ABCD cohorts 
(Table S3). Whilst not passing the bonferroni corrected 
p-threshold PC(38:5) was significantly (p < 0.05) associ-
ated with HDL concentration in both plasma and DBS 
samples (Table S3).
With the exception of CE(14:0) and TG(47:4) which 
were not measured in dried blood spot samples all lipids 
were significantly associated with LDL concentration in 
both sample types passing a bonferroni correct p-thresh-
old (p < 0.0004) (Table S4).
Of the 11 lipids total cholesterol concentration all were 
significantly (p < 0.05) associated with total cholesterol 
concentration however only 7 passed a bonferroni cor-
rect p-threshold (p < 0.0004) with CE(18:2), PC-O(34:1), 
PC-O(40:5) and TG(56:5) falling short. In dried blood 
spots CE(14:0), CE(16:1), LPC(20:4) and PC-O(40:5) 
which were not measured, however the remaining 7 meas-
ured lipids were all significantly associated with total 
concentration and passed multiple comparison correction 
based on bonferroni correct p-threshold (p < 0.0004) with 
all of these lipids also exhibiting a stronger association 
than is observed between these lipids and total choles-
terol concentration than is seen in the discovery cohort 
(Table S5).
3.6  Stratification based on estimated lipoprotein 
concentration
Plasma samples were stratified into the clinical risk cat-
egories based on their estimated lipoprotein concentration 
(Table 2). Total classification accuracies of 83.9%, 64.9%, 
82.2%, and 64.9% were obtained for triglyceride, HDL, 
LDL and total cholesterol respectively (Table 2). Classifi-
cation accuracy was not equal across the groups for any of 
the lipoproteins, with the risk category with the most sam-
ples in it having the highest accuracy with the exception of 
the ‘low risk’ total group which only contained 3 samples.
Stratification of DBS samples in the ABCD cohort 
was based on quartile rather than clinical cut-offs as the 
samples came from adolescents only 3% of the measure-
ments fell outside of the healthy range. Classification 
accuracy was not equal across the quartiles with all of the 
Fig. 3  Scatter plots showing predicted vs. measured LDL concentration in discovery and validation analysis. a Results of model trained and 
tested in ‘discovery’ cohort. b Results of models trained and tested in DBS ‘validation’ cohort using lipid markers identified in plasma
Fig. 4  Scatter plots showing predicted vs. measured total cholesterol 
concentration in discovery and validation analysis. a Results of model 
trained and tested in ‘discovery’ cohort. b Results of models trained 
and tested in DBS ‘validation’ cohort using lipid markers identified 
in plasma
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lipoproteins showing better classification accuracy in the 
1st and 4th quartiles (Table 2).
4  Discussion
To our knowledge this is the first study to compare results 
obtained from DBSs and plasma samples in complex lipi-
domics studies and to determine that if we tried to answer 
the same biological question in both sample types would 
we achieve the same answer. Whilst we measured more 
lipids from the plasma samples (163 compared to 118) a 
high proportion (71%) of the lipids measured in the DBS 
samples were also measured in plasma, with this lower 
number of lipids likely the result of less biological mate-
rial being obtained from a single DBS punch than was 
extracted for the plasma samples.
Applying random forest machine learning to the lipid 
profile data generated from the plasma samples we were 
able to obtain good estimates (r > 0.7) of the concentra-
tion of triglyceride (12 lipid panel) and HDL (11 lipid 
panel) and modest estimates (r > 0.4) of LDL (10 lipid 
panel) and total cholesterol (11 lipid panel) When these 
lipids were measured in an independent cohort of DBS 
samples 2 of the TG markers were not measured whilst 
the other 10 validated the association seen in the plasma 
samples. For HDL all 11 lipids validated, for LDL 2 were 
not measured and 8 validated and for total cholesterol 4 
lipids were not measured in DBS while the remaining 7 
lipids validated between cohorts. Using these panels of 
lipid biomarkers identified in plasma samples we were 
also able to use them to obtain a good estimate of tri-
glyceride concentration and modest estimates of HDL, 
LDL and total cholesterol concentrations. This begins to 
suggest that dried blood spots can be used as an alterna-
tive to plasma samples and that the process of adding 
and removing the sample from the card is not altering 
the composition of the lipidome and its association with 
relationship with outcome measures, in this case the 
concentration of the four ‘clinical lipids’. This finding 
is keeping with previous reports that have shown DBS 
as a viable alternative (Koulman et al. 2014; Mahajan 
et al. 2018) however this is the first study to directly this 
comparability.
We also wanted to see if the concentration estimates 
generated from both plasma and DBS samples were accu-
rate enough to be used in clinical practice. Knowing a 
patients exact concentration of TriG, HDL, LDL or total 
cholesterol is less important than knowing their relative 
concentration (https ://www.nhs.uk/condi tions /high-chole 
stero l/chole stero l-level s/; Nantsupawat et al. 2019), i.e. if 
they fall outside of the healthy range, with a well-defined 
set of cut-offs described for each of the four ‘clinical 
lipids’ (https ://www.nhs.uk/condi tions /high-chole stero l/
chole stero l-level s/; Nantsupawat et al. 2019). In plasma 
our estimated concentrations classified people into the cor-
rect clinical category with accuracies of 83.9%, 64.9%, 
82.2%, and 64.9% for triglyceride, HDL, LDL and total 
cholesterol respectively. However, it is generally accepted 
that clinical biomarkers and test should have a sensitivity 
and specificity over 90% (“Biomarkers: portents of malig-
nancy”). So whilst these accuracies are all significantly 
higher than we would expect to see if we assigned indi-
viduals to groups randomly, but they are not good enough 
to be used in clinical practice. In the DBS cohort, looking 
at clinical cut-offs was inappropriate as the samples came 
from children with only 3% of the measurements falling 
outside of the healthy range, instead we looked at the rela-
tive distribution based on quartiles. As with plasma sam-
ples this is higher classification accuracy than we would 
expect if we assigned individuals to groups randomly but 
it still falls well short of the 90% sensitivity and specificity 
required for clinical practice.
Whilst the estimates that we have obtained in this study 
are not currently accurate enough for clinical use there does 
appear to be room for improvement. Looking at both plasma 
and DBS sample it can be seen that the risk category that 
most samples belong to being the most accurately classified 
as there was an overall bias with an significant over esti-
mation of concentrations in this range (Table 2). This bias 
occurs because during the training phase the model identifies 
the optimum parameters to obtain the best prediction accu-
racy possible. So if the samples are clustered at the bottom 
of the concentration range, then the model will be biased 
towards predicting low concentrations as this will increase 
prediction accuracy for example in a situation where we 
have no information about a sample based on probability 
it is more likely to have a low concentration than a high 
one. Triglyceride has a more even distribution across the 
measure concentration range in both plasma and DBS (and 
as a result of this we for this lipoprotein we see a stronger 
correlation between estimated and measured concentration 
as well as a higher accuracy when assigning individuals to 
clinical groups relative to the other three lipoproteins in both 
plasma and DBS samples.
Whilst fewer lipids were measured in dried blood spots 
relative to plasma samples lipid markers used to predict 
the concentration of lipoproteins in plasma also predict 
their concentration when measured in DBS samples. This 
demonstrates that dried blood spots have the same associa-
tion between the lipid profile of the sample and the clinical 
outcome.
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